摘要
目的:探讨吸入用布地奈德混悬液联合头孢曲松钠对支气管肺炎患儿治疗效果。方法:回顾性收集2022年9月至2024年1月期间本院诊治的120例支气管肺炎患儿的临床资料。按不同治疗方法将患儿分为对照组(n=58)采用头孢曲松钠20-80 mg·kg-1静脉滴注治疗,观察组(n=62)基于对照组加用布地奈德混悬液0.2 mg雾化吸入治疗,两组持续用药1 w。分析比较两组的临床疗效、症状消失时间,于治疗前后采用肺功能检测仪检测用力肺活量(Forced vital capacity,FVC)、呼气峰流量(Peak expiratory flow,PEF)、第1秒用力呼气容积(Forced expiratory volume in one second,FEV1)、FEV1/FVC,采用化学发光免疫分析法测定降钙素原(Procalcitonin,PCT),同时采用酶联免疫吸附法测定可溶性细胞间黏附分子-1(Soluble intercellular cell adhesion molecule-1,sICAM-1)、可溶性白细胞介素-2受体(Soluble interleukin-2 receptor,sIL-2R)、可溶性髓系细胞触发受体-1(Soluble triggering receptor expressed on myeloid cells-1,sTREM-1)水平,并分析比较两组不良反应发生率。结果:观察组的治疗总有效率显著高于对照组(P<0.05)。观察组的肺部啰音、喘息、气促、咳嗽消失时间均比对照组显著缩短(P<0.05)。治疗后,观察组的PEF、FVC、FEV1、FEV1/FVC均显著高于对照组(P<0.05)。治疗后,观察组的PCT、sICAM-1、sIL-2R、sTREM-1水平均显著低于对照组(P<0.05)。两组的不良反应总发生率无显著差异(P>0.05)。结论:支气管肺炎患儿经吸入布地奈德混悬液联合头孢曲松钠治疗,能提高治疗效果,改善肺功能,减轻临床症状,降低机体炎症反应,且安全性较高。
Objective:To investigate the therapeutic effect of inhaled budesonide suspension combined with ceftriaxone sodium on children with bronchial pneumonia.Methods:The clinical data of 120 children with bronchial pneumonia treated in our hospital from September 2022 to January 2024 were retrospectively collected.The children were divided into a control group(n=58)treated with intravenous infusion of ceftriaxone sodium 20-80 mg·kg-1 and an observation group(n=62)treated with additional nebulization inhalation of budesonide suspension 0.2 mg based on the control group.Both groups were treated for 1 week.The clinical efficacy and symptom disappearance time of the two groups were analyzed and compared.Before and after treatment,forced vital capacity(FVC),peak expiratory flow(PEF),forced expiratory volume in one second(FEV1),forced expiratory volume in five seconds(FEV5),forced expiratory volume in ten seconds(FEV10),FEV1),FEV1/FVC,the levels of Procalcitonin(PCT),Soluble intercellular cell adhesion molecule-1(sICAM-1),Soluble interleukin-2 receptor(sIL-2R),and Soluble triggering receptor expressed on myeloid cells-1(sTREM-1)were measured using the enzyme-linked immunosorbent assay(ELISA)and chemiluminescent immunoassay(CLIA)methods,respectively.The incidence of adverse reactions in the two groups was analyzed and compared.Results:The total effective rate of observation group was significantly higher than that of control group(P<0.05).The disappearance time of lung rales,wheezing,shortness of breath and cough in observation group was significantly shorter than that in control group(P<0.05).After treatment,PEF,FVC,FEV1 and FEV1/FVC in observation group were significantly higher than those in control group(P<0.05).After treatment,the levels of PCT,sICAM-1,sIL-2R and sTREM-1 in observation group were significantly lower than those in control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Inhalation of budesonide suspension combined with ceftriaxone sodium can improve the therapeutic effect,improve lung function,alleviate clinical symptoms and reduce inflammation in children with bronchial pneumonia,with high safety.
作者
张蕾
方华
陈凤
Zhang Lei;Fang Hua;Chen Feng(Department of Pediatrics,Xinyang Central Hospital,Xinyang 464000,Henan,China)
关键词
吸入用布地奈德混悬液
头孢曲松钠
支气管肺炎
临床疗效
肺功能
Budesonide suspension for inhalation
Ceftriaxone sodium
Bronchopneumonia
Clinical effect
Lung function
作者简介
张蕾,女,主治医师,主要从事儿童消化内科,呼吸内科相关临床工作,Email:ZL691800869@139.com。
